MEDA Pharma

This sponsor has funded 6 studies across 9 countries.

PAS funded by this sponsor.
EU PAS ID Status Title Protocol uploaded Results uploaded
4414 Finalised Profile of patients prescribed Dymista® (azelastine hydrochloride/ fluticasone propionate) nasal spray for allergic rhinitis in the UK No No
11134 Finalised Retrospective Chart Review to Evaluate the Effectiveness of the Risk Minimization Measures for the Use of Flupirtine 100 mg Immediate-Release Capsules... No Yes
12171 Ongoing Retrospective Cohort Study on the Risk of Venous Thromboembolism with the use of combined oral contraceptives containing Chlormadinone... No No
12177 Finalised Drug Utilization Study to Characterize the Prescribing Practice of Flupirtine-containing Medicinal Products during Typical Clinical Use and to Assess... No No
22774 Finalised Observational study on persistent allergic rhinitis patients to evaluate effectiveness of Dymista® nasal spray in daily practice No No
23075 Finalised Observational study to evaluate the actual use of Dymista® nasal spray in different allergic rhinitis patient phenotypes No No

PAS by Risk Management Plan (RMP) requirement

MEDA Pharma

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.